

**REMARKS**


Applicants elect the Group II invention without traverse. Claims drawn to the Group I and Group III inventions have been canceled without prejudice or disclaimer.

Claim 8-13, all of Group II, have been amended to a form more suitable for examination. As discussed in the application, VEGF receptor concentration should be elevated at the first day of an angioplasty to bind excessive VEGF and thus control upregulated growth. Typically, in angioplasty, VEGF is released in high concentration from the first day and, as a consequence of the release of VEGF, on expression of the VEGF receptor in the coronary blood vessels can be observed after 4-5 days. However, delayed expression may cause restenosis. Claims 8-13 now specify that a patient is provided with the VEGF receptor gene or gene product to prevent or inhibit restenosis.

Please proceed to an examination on the merits.

A provisional petition is hereby made for any extension of time necessary for the continued pendency during the life of this application. Please charge any fees for such provisional petition and any deficiencies in fees and credit any overpayment of fees to Attorney's Deposit Account No. 50-2041.

Respectfully submitted,



Michael E. Whitham  
Reg. No. 32,635

Whitham, Curtis, Christofferson & Cook, P.C.  
11491 Sunset Hills Road, Suite 340  
Reston, VA 20190

Tel. (703) 787-9400  
Fax. (703) 787-7557

Customer No.: 30743